Rob Fox

Rob Fox began their work experience in 2003 at Idis, where they held various roles in business development, including European Business Development Manager, Account Director, and Business Development Executive. In 2010, they became a Global Business Development team member, focusing on early access, clinical trial solutions, and global access for unlicensed medicines. From 2010 to 2014, they served as the Director of Global Business Development, working with strategic accounts and developing early access solutions for patients with unmet medical needs. In 2014, they became the Vice President of Global Business Development, leading the team in defining managed access strategies and programs. In 2015, Idis was acquired by Clinigen, and Rob continued their career at Clinigen as the Head of Business Development - Managed Access. Rob later became the VP of Corporate Development, overseeing cross divisional business development activities. In 2021, they became the VP of Investor Relations and Corporate Development, responsible for managing investor relationships and communicating strategy and performance to the markets. In 2022, they became a key member of the Corporate Development team, responsible for maximizing growth opportunities across the Clinigen Group. Throughout their career, Rob has demonstrated strong leadership skills and expertise in pharmaceutical business development and managed access solutions.

Rob Fox attended the University of Liverpool from 1995 to 1998, where they obtained a BA Hons degree in Business Economics. In addition to their degree, they have obtained certifications in Corporate Finance and Strategy from The London School of Economics and Political Science (LSE) and in Mergers and Acquisitions from Imperial College Business School in 2023.